|
TAF8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
5.15260001332507E-09 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62481139653892E-12 |
| Stage1-vs-Stage2 |
7.519800E-02 |
| Stage1-vs-Stage3 |
1.228630E-01 |
| Stage1-vs-Stage4 |
4.723500E-02 |
| Stage2-vs-Stage3 |
6.938600E-03 |
| Stage2-vs-Stage4 |
2.635500E-03 |
| Stage3-vs-Stage4 |
4.440200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-16 |
| Normal-vs-AfricanAmerican |
1.76160000031622E-07 |
| Normal-vs-Asian |
1.7973955657169E-11 |
| Caucasian-vs-AfricanAmerican |
1.548630E-01 |
| Caucasian-vs-Asian |
1.063800E-01 |
| AfricanAmerican-vs-Asian |
8.194600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.617000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.15130000000185E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.550800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.083400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.785400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.053800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.714400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.420000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.243500E-04 |
| Classical-VS-Follicular |
2.626400E-02 |
| Classical-VS-Other |
6.042200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
3.59920000003733E-06 |
| Tall-VS-Other |
2.761600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.691800E-01 |
| Follicular-VS-Normal |
8.45079561884177E-11 |
| Other-VS-Normal |
4.4123000000007E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
3.33066907387547E-16 |
| N0-vs-N1 |
1.899500E-02 |
|
|
